Search clinical trials for: Unconjugated IDEC-159

Total 4223 results

Biogen

Terminated

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

Colorectal Cancer | Metastases

United States
Biogen

Completed

Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Hansa Biopharma AB

Recruiting

A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group (PAES-LTFU)

Long Term Efficacy and Safety

Spain, Czechia
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Waldenström Macroglobulinemia | Post-transplant Lymphoproliferative Disorder | Stage III Adult Burkitt Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Burkitt Lymphoma | Stage IV Adult Diffuse...

United States
Major Extremity Trauma Research Consortium
United States Department of Defense

Completed

PRIORITI-MTF Study- Testing Patient Response to the IDEO (PRIORITI-MTF)

Leg Injuries | Trauma

United States
Case Comprehensive Cancer Center

Terminated

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma

Primary Central Nervous System Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Terminated

17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Hansa Biopharma AB

Completed

A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation

Kidney Transplant Failure and Rejection

United States, Sweden, France
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone... and other conditions

United States
Bridor

Completed

Bread Daily Intake Enriched With Mix Fibers in Metabolic Subjects: Intestinal Microbiota and Metabolic Profile Impact (Breath)

Healthy Obesity, Metabolically

France
Ohio State University Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States
Kami Maddocks, MD
Novartis

Completed

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States
Dana-Farber Cancer Institute
HiberCell, Inc.

Completed

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

United States
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

Langerhans Cell Histiocytosis | LCH

China
Shanghai Fosun Pharmaceutical Industrial Development...

Suspended

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

Melanoma

China
University of Arizona
National Cancer Institute (NCI)

Completed

Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Anaplastic Large Cell Lymphoma

United States
Hansa Biopharma AB
Karolinska Institutet; Uppsala University Hospital

Completed

Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation

End Stage Kidney Disease

Sweden
Hansa Biopharma AB

Recruiting

Imlifidase Prior to Kidney Transplant in Highly Sensitised Children (DINKY)

Kidney Transplantation in Highly Sensitized Patients

Spain, Finland, Sweden
Hansa Biopharma AB

Active, not recruiting

A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation

Kidney Transplantation in Highly Sensitized Patients

United States
Hansa Biopharma AB

Terminated

An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR

Kidney Transplant Rejection

Germany, France, Austria
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Post-transplant Lymphoproliferative Disorder | Recurrent Childhood Large Cell Lymphoma | Recurrent Childhood Lymphoblastic Lymphoma | Recurrent Childhood Small Noncleaved Cell Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | AIDS-related Peripheral/Systemic Lymphoma | AIDS-related...

United States
National Cancer Institute (NCI)

Completed

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Shanghai Fosun Pharmaceutical Industrial Development...

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Neurofibromatosis 1 | NF1 | Plexiform Neurofibroma

United States, China, Spain
National Cancer Institute (NCI)

Terminated

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Stage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular Lymphoma

United States
Mersana Therapeutics

Completed

A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors (XMT-1107)

Neoplasm Metastasis

United States
Duramed Research

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

Menopause

United States
Hansa Biopharma AB

Completed

Safety Study on IdeS in Healthy Volounteers

Healthy

Sweden
IDEA AG

Completed

IDEA-033 Open Label Study

Joint Pain | Musculoskeletal Pain | Stiffness | Soft Tissue Inflammation in Designated Target Area(s)

Germany
IDEA AG

Completed

Effect of IDEA-070 on Pain and Inflammation Induced by PDT

Actinic Keratosis

Germany
Biogen

Completed

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Gladwin, Mark, MD

Completed

The Effects of NOx and Conjugated Linoleic Acid on Asthmatics (NICLA)

Asthma

United States
Janssen Inc.

Completed

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Psoriasis

United States, Poland, Canada, Belgium, Germany
Hansa Biopharma AB
University College London Hospitals

Terminated

IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients

Purpura, Thrombotic Thrombocytopenic

United Kingdom
Lee, Stephanie
National Cancer Institute (NCI)

Completed

Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

Systemic Scleroderma | Graft Versus Host Disease

United States
National Cancer Institute (NCI)

Completed

CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recurrent Mantle Cell Lymphoma

United States
PegBio Co., Ltd.
Covance

Completed

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Hansa Biopharma AB

Completed

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

Kidney Transplant Rejection

Australia, United States, Germany, France, Austria
Duramed Research

Completed

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

Nocturnal Vasomotor Symptoms

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma

Lymphoma

United States
Liverpool John Moores University
University of Central Lancashire; Queen's University, Belfast; Newcastle University and other collaborators

Completed

Idea Density in Exam Performance (IDEP)

Medical Education | Health Education | Educational Assessment

United Kingdom
Hansa Biopharma AB

Recruiting

Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts (PAES)

Kidney Transplantation in Highly Sensitized Patients

Spain, Italy, France, Netherlands, Belgium, Austria, Czechia, Sweden, United Kingdom, Slovenia
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone... and other conditions

United States
University of Alabama at Birmingham
National Cancer Institute (NCI); Biogen

Completed

Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Biogen

Completed

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Duramed Research

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

Menopause

United States
TriHealth Inc.

Completed

The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse

Pelvic Organ Prolapse | Vaginal Atrophy

United States
Biogen

Completed

Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases

Colorectal Carcinoma | Metastases

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

Search clinical trials for: Unconjugated IDEC-159

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations